Welcome to our dedicated page for Pro-Dex Colo news (Ticker: PDEX), a resource for investors and traders seeking the latest updates and insights on Pro-Dex Colo stock.
Pro-Dex Inc (PDEX) delivers precision-engineered medical devices and motion control systems for surgical and industrial applications. This news hub provides investors and industry professionals with authoritative updates on the company’s latest developments.
Access real-time announcements including product launches, financial results, and strategic partnerships. Our curated collection ensures you stay informed about PDEX’s innovations in torque-limiting surgical tools, multi-axis automation systems, and engineering services.
Key coverage areas include regulatory milestones, manufacturing expansions, and technology patents. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Pro-Dex Inc’s evolving role in medical device innovation and industrial automation. Check regularly for updates directly impacting market positioning and technical advancements.
Pro-Dex, Inc. (NasdaqCM:PDEX) reported its fiscal 2023 second-quarter financial results for the period ended December 31, 2022. Net sales rose by $1.1 million (11%) to $11.3 million, driven by increased sales and repair revenue from orthopedic surgical handpieces. However, gross profit decreased by $781,000 (23%) to $2.6 million due to rising component costs and higher repair expenses. Operating expenses decreased by $316,000 (18%) to $1.5 million. Net income for the quarter was $879,000 ($0.24 per diluted share), a slight drop from $925,000 ($0.25 per diluted share) in the previous year. The company anticipates growth as operations commence at its new facility.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a Q1 fiscal 2023 net sales increase to $11.1 million, up 11% from $10.0 million in Q1 fiscal 2022. This growth was attributed to a $0.8 million rise in surgical handpiece repairs and a $0.7 million boost in NRE and prototype sales. However, medical device sales dipped by $397,000. The gross profit fell by 14% to $2.99 million, yielding a gross margin decrease to 27%. Net income remained stable at $1.1 million, with earnings per diluted share rising to $0.29. The FDA has authorized manufacturing at the Franklin facility, and negotiations with the largest customer are expected to yield further revenue.
Pro-Dex, Inc. (NasdaqCM:PDEX) reported its fiscal 2022 fourth quarter and full-year results on August 25, 2022, showing a 34% increase in quarterly net sales to $12.6 million. Annual net sales rose 11% to $42.0 million, driven mainly by orthopedic device sales. However, gross profit decreased 3% year-over-year to $13.1 million, while net income for the year was $3.9 million, down from $5.8 million. Operating expenses decreased 12% due to reduced R&D costs. Supply chain disruptions were noted, but the company remains optimistic about future growth.
Pro-Dex reported Q3 fiscal 2022 results, revealing a 21% decline in net sales, totaling $9.3 million, primarily due to decreased thoracic driver sales. Gross profit fell 35% to $2.9 million, attributed to increased component costs amid supply chain challenges. Operating expenses decreased 27% to $1.9 million. Net income dropped 78% to $462,000 or $0.12 per diluted share. However, year-to-date sales increased 3% to $29.4 million. CEO Van Kirk expressed optimism for Q4, citing a healthy backlog and secured components.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a robust fiscal 2022 second quarter with net sales up 23% to $10.2 million, driven by orthopedic surgical handpiece sales. Gross profit rose 31% to $3.4 million, and operating expenses declined by 13% to $1.8 million. However, net income fell to $925,000 ($0.25 per diluted share) compared to $1.8 million ($0.44) from the same quarter last year. Looking ahead, Pro-Dex warns of supply chain challenges that could reduce net sales in the upcoming quarters but remains optimistic about long-term prospects.
Pro-Dex, Inc. (NasdaqCM:PDEX) reported a 16% increase in net sales for Q1 fiscal 2022, totaling $10.0 million compared to $8.6 million in Q1 2021. The growth stemmed from higher sales of surgical handpieces and CMF drivers, though sales of a thoracic driver decreased. Gross profit fell by $47,000, with a margin of 34% down from 40%. Operating expenses rose $184,000, while net income decreased to $1.1 million, or $0.28 per share. The company is advancing internal projects and preparing to relocate employees to a new facility.
Pro-Dex reported Q4 2021 net sales of $9.4 million, a 15% decrease from $11.1 million in Q4 2020, primarily due to lower medical device sales following two previous product launches. Gross profit fell by 27% to $3.1 million, driven by decreased sales and price concessions. Operating expenses increased by 21% to $2.5 million. Yearly results showed a 9% sales increase to $38 million, with a slight gross profit rise to $13.6 million. However, net income for the year decreased to $4.5 million from $6.1 million, attributed to higher operating expenses and R&D investments.
Pro-Dex reported a 38% increase in net sales for Q3 FY2021, reaching $11.7 million, driven by strong performance in thoracic drivers. Gross profit also rose 37% to $4.4 million. Net income increased to $2.0 million ($0.50 per diluted share) from $1.2 million ($0.30 per diluted share) year-over-year. However, operating expenses surged by 67% due to heightened investment in product development. For the nine months ended March 31, 2021, sales rose 21% to $28.6 million, with net income stable at $3.6 million. The CEO expressed pride in team performance amid challenges during the pandemic.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a 4% increase in net sales for the second quarter of fiscal 2021, totaling $8.3 million, driven by new product sales. However, gross profit declined 9% to $2.6 million due to under-absorbed fixed manufacturing costs. Operating expenses surged 74% to $2.1 million as the company invested in R&D and administrative functions. Net income fell to $337,000 or $0.08 per diluted share, down from $1.2 million or $0.31 per diluted share a year earlier. Year-to-date net sales grew 11% to $16.9 million.
Pro-Dex reported a 19% increase in net sales for Q1 fiscal 2021, totaling $8.6 million, up from $7.2 million in Q1 fiscal 2020. The gross profit rose 25% to $3.5 million, with a gross margin of 40%. Operating expenses increased by $637,000, reflecting investments in R&D for new product launches. Net income for the quarter was $1.3 million, or $0.32 per diluted share, compared to $1.1 million or $0.27 in the prior year. CEO Richard Van Kirk expressed optimism about future product releases, including a new ENT shaver and CMF driver.
